Xspray Announces 2 Poster Presentations for XS004 in Chronic Myeloid Leukemia (CML) at the American Society of Hematology (ASH) 2022 Annual Meeting

Xspray Announces 2 Poster Presentations for XS004 in Chronic Myeloid Leukemia (CML) at the American Society of Hematology (ASH) 2022 Annual Meeting Press release 2022-11-03 Xspray Pharma AB (NASDAQ Stockholm: XSPRAY), a biopharmaceutical company focused on developing improved, amorphous forms of TKIs, announces two poster presentations of data for XS004 in patients with chronic myeloid leukemia (CML) at the 64th annual American Society of Hematology (ASH) meeting December 10-13 in New Orleans, USA. “As patients live longer with hematologic malignancies, there is a need to optimize treatments and improve patient experience over the long-term. Through our patented HyNap technology platform, Xspray develops improved amorphous oncology products with the potential to address real-world challenges that impact outcomes and quality of life. We are pleased to participate in ASH this year and present data that may be highly relevant for the CML community,” says Per Andersson, CEO of Xspray Pharma. The US Food and Drug Administration (FDA) has granted XS004 orphan drug designation in the use of the treatment of chronic myeloid leukemia (CML). XS004 is currently under FDA review for market approval under the 505(b)(2) NDA regulatory pathway. The following two abstracts will be presented: Poster title: Comedication of Proton Pump Inhibitors and Dasatinib Is Common in CML but XS004, a Novel Amorphous Solid Dispersion Formulation of Dasatinib, Provides Improved Uptake and Low pH-Dependency, Minimizing Unwanted Drug-Drug Interactions Poster number: 3013 First author: Gunnar Larfors, MD, PhD, Department of Medical Sciences, Unit of Hematology, Uppsala University, Sweden Presentation date and location: Sunday, December 11, 6:00 PM – 8:00 PM, Ernest N. Morial Convention Center, Hall D Poster title: XS004 Dasatinib (XS004) Improves Variability and Bioavailability in Humans Using Amorphous Solid Dispersion Formulation of Dasatinib with Potential Implications for Its Clinical Use Poster number: 4341 First author: Hans Lennernäs, Professor at Department of Pharmaceutical Biosciences, Translational Drug Discovery and Development, Uppsala University, Sweden Presentation date and location: Monday, December 12, 6:00 PM – 8:00 PM, Ernest N. Morial Convention Center, Hall D For further information, please contact: Christina Malmberg Hägerstrand Senior Vice President Communications & Investor Relations Xspray Pharma AB Mob: +46 (0) 72 855 93 29 E-mail: [email protected] About Xspray Pharma Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development. Xspray Pharma uses its innovative, patented RightSize™ technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high. The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today’s original drugs before the secondary patents expire. Xspray’s goal is to become the leader in the development of improved drugs of PKIs already marketed for the treatment of cancer, which numbered to 72 in the end of 2021. The company has patented manufacturing technology, equipment, and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). www.xspraypharma.com Attachments Xspray Announces 2 Poster Presentations for XS004 in Chronic Myeloid Leukemia (CML) at the American Society of Hematology (ASH) 2022 Annual Meeting

The release as fetched from its publisher. xspraypharma.com ↗